Drug Trial Radar · NCT05278208
Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors
Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
65
Planned (sponsor's estimate)
Start
Nov 21, 2022
Primary completion
Nov 2028
Study completion Nov 2033
Sponsor
- Lead sponsor
- Nationwide Children's HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Mar 14, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 4 years, up to 39 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the safety and efficacy of Lutathera (177Lu-DOTATATE) in patients with progressive or recurrent High-Grade Central Nervous System (CNS) tumors and meningiomas that demonstrate uptake on DOTATATE PET. The drug will be given intravenously once every 8 weeks for a total of up to 4 doses over 8 months in patients aged 4 to \<12 years (Phase I) or 12 to \</=39 years (Phase II) to test its safety and efficacy, respectively. Funding Source - FDA OOPD (grant number FD-R-0532-01)
Conditions
- High Grade Glioma
- Meningioma
- Embryonal Tumor
- Medulloblastoma
- Anaplastic Ependymoma
- Recurrent Diffuse Intrinsic Pontine Glioma
- Recurrent Malignant Glioma
- Recurrent Medulloblastoma
- Recurrent Primary Central Nervous System Neoplasm
- Refractory Diffuse Intrinsic Pontine Glioma
- Refractory Malignant Glioma
- Refractory Medulloblastoma
- Refractory Primary Central Nervous System Neoplasm
Interventions
LUTATHERA® (Lutetium Lu 177 dotatate)Drug
Lutathera: IV administration maximum dose of 200 mCi once every 8 weeks (one cycle) for total of 4 cycles (8 months)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Estimate MTD of Lutathera in pediatric CNS patients 4 to <12 yearsTime frame: up to 8 months
- Estimate RP2D of Lutathera in pediatric CNS patients 4 to <12 yearsTime frame: up to 8 months
- Calculate the incidence of treatment related adverse events as assessed by CTCAE v5.0 in pediatric (4 to <12 yo) CNS patients treated with LutatheraTime frame: up to 2 months
- Assess PFS of Lutathera in CNS patients 12 to </=39 yearsTime frame: up to 6 months
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Children's Hospital Colorado
Aurora, Colorado · Withdrawn
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio · Recruiting
Nationwide Children's Hospital
Columbus, Ohio · Recruiting
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.